Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 15/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17265862 | 0.79 | ESR1 (0.61) | ESR1ESR2APPSTSNPC1 | |
| SCHEMBL895172 | 0.79 | PIK3CG (0.66) | NPC1RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL29999385 | 0.79 | ESR1 (0.61) | ESR1ESR2APPSTSNPC1 | |
| SCHEMBL12778279 | 0.76 | ESR1 (0.58) | ESR1ESR2APPSTSNPC1 | |
| SCHEMBL1562323 | 0.76 | ESR1 (0.58) | ESR1ESR2APPSTSNPC1 | |
| SCHEMBL2541637 | 0.76 | KDM4E (0.59) | NPC1RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL11170826 | 0.76 | PIK3CG (0.43) | ESR1ESR2NPC1RAB9AKDM4E | |
| SCHEMBL20552113 | 0.76 | PIK3CG (0.43) | KDM4EALDH1A1MAPTHTTPIK3CG | |
| SCHEMBL15157800 | 0.76 | NPC1 (0.58) | NPC1RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL1655937 | 0.76 | ESR1 (0.58) | ESR1ESR2APPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162871-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024084447-A2 | AZETIDINYL BENZOXAZOLE COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| WO-2007121484-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121484-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6686357-B1 | BENZIMIDAZOLO-PIPERIDINE COMPOUND | PFIZER, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6509464-B1 | 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation | PFIZER INC | 2003-01-21 | — | — | US | disclosed |
| US-6495549-B1 | 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE | PFIZER INC | 2002-12-17 | — | — | US | disclosed |
| EP-1098894-B1 | FKBP INHIBITORS | PFIZER LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| EP-1098894-A1 | FKBP INHIBITORS | Pfizer Limited (GB) | 2001-05-16 | — | — | EP | disclosed |
| US-6166011-A | FKBP inhibitors | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000005231-A1 | FKBP INHIBITORS | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787791-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885APP 3512/4885 |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885APP 3512/4885 |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885APP 3512/4885 |
| US-12162871-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | ESR1 4245/4885ESR2 3315/4885APP 3512/4885 |
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | FKBP1A, FKBP4, FKBP1B | ESR1 3454/4885ESR2 4393/4885APP 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.